Abstract
Epidermal Growth Factor Receptor (EGFR) is a transmembrane glycoprotein that constitutes one of the four members of ErbB family of tyrosine kinase receptors. Activation of EGFR leads to autophosphorylation of receptor tyrosine kinase that initiates a cascade of downstream signaling pathways involved in regulating cellular proliferation, differentiation, and survival. EGFR is abnormally activated by various mechanisms like receptor overexpression, mutation, ligand-dependent receptor dimerization, ligand-independent activation and is associated with the development of variety of human cancers. EGFR inhibition is one of the key targets for cancer chemotherapy. Approval of tyrosine kinase inhibitors such as erlotinib, gefitinib, and lapatinib for the treatment of non-small cell lung cancer led to tremendous development of novel EGFR inhibitors in the last decade. Diverse class of chemical compounds from the synthetic origin has been extensively studied. This review highlights the various classes of synthetically derived molecules which have been reported in the last few years as potential EGFR and EGFR/ErbB-2 dual inhibitors. A brief synthetic methodology to access these compounds has been highlighted along with the SAR. We strongly believe that this review will provide a platform to the synthetic chemists and biologists to design and synthesize new and potent compounds that inhibit EGFR and ErbB-2.
Keywords: Antibodies, Apoptosis, Carcinoma, EGFR, Heterocyclic, Proliferation.
Mini-Reviews in Medicinal Chemistry
Title:Review on EGFR Inhibitors: Critical Updates
Volume: 16 Issue: 14
Author(s): Davinder Singh, Bhupinder Kumar Attri, Rupinder Kaur Gill and Jitender Bariwal
Affiliation:
Keywords: Antibodies, Apoptosis, Carcinoma, EGFR, Heterocyclic, Proliferation.
Abstract: Epidermal Growth Factor Receptor (EGFR) is a transmembrane glycoprotein that constitutes one of the four members of ErbB family of tyrosine kinase receptors. Activation of EGFR leads to autophosphorylation of receptor tyrosine kinase that initiates a cascade of downstream signaling pathways involved in regulating cellular proliferation, differentiation, and survival. EGFR is abnormally activated by various mechanisms like receptor overexpression, mutation, ligand-dependent receptor dimerization, ligand-independent activation and is associated with the development of variety of human cancers. EGFR inhibition is one of the key targets for cancer chemotherapy. Approval of tyrosine kinase inhibitors such as erlotinib, gefitinib, and lapatinib for the treatment of non-small cell lung cancer led to tremendous development of novel EGFR inhibitors in the last decade. Diverse class of chemical compounds from the synthetic origin has been extensively studied. This review highlights the various classes of synthetically derived molecules which have been reported in the last few years as potential EGFR and EGFR/ErbB-2 dual inhibitors. A brief synthetic methodology to access these compounds has been highlighted along with the SAR. We strongly believe that this review will provide a platform to the synthetic chemists and biologists to design and synthesize new and potent compounds that inhibit EGFR and ErbB-2.
Export Options
About this article
Cite this article as:
Singh Davinder, Attri Kumar Bhupinder, Gill Kaur Rupinder and Bariwal Jitender, Review on EGFR Inhibitors: Critical Updates, Mini-Reviews in Medicinal Chemistry 2016; 16 (14) . https://dx.doi.org/10.2174/1389557516666160321114917
DOI https://dx.doi.org/10.2174/1389557516666160321114917 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Angiogenesis by the Small Heat Shock Protein αB-Crystallin
Current Angiogenesis (Discontinued) AKT Signaling in Regulating Angiogenesis
Current Cancer Drug Targets Targeting miR-21 Induces Autophagy and Chemosensitivity of Leukemia Cells
Current Drug Targets Medicinal Chemistry of Probimane and MST-16: Comparison of Anticancer Effects Between Bisdioxopiperazines
Medicinal Chemistry Current Development of ROS-Modulating Agents as Novel Antitumor Therapy
Current Cancer Drug Targets New Antitumour Natural Products from Marine Red Algae: Covering the Period from 2003 to 2012
Mini-Reviews in Medicinal Chemistry Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Clofarabine as a Novel Nucleoside Analogue Approved to Treat Patients with Haematological Malignancies: Mechanism of Action and Clinical Activity
Mini-Reviews in Medicinal Chemistry Computational & Statistical Methodologies to Identify Biomarkers in Cancer
Current Cancer Therapy Reviews MicroRNA Gene Networks in Oncogenesis
Current Genomics Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents Methionine AminoPeptidase Type-2 Inhibitors Targeting Angiogenesis
Current Topics in Medicinal Chemistry Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles
Current Pharmaceutical Design Editorial (Thematic Issue: Targeting Anti-Cancer Agents and Cancer Treatments)
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Signal Transduction of Natural Products for Anticancer Therapy)
Current Signal Transduction Therapy Tomographic Imaging Methods and Gated Technique in Nuclear Cardiology: A Review on Current Status and Future Developments
Recent Patents on Medical Imaging Stage N2/IIIA Non Small Cell Lung Cancer: An Evidence-Based Review
Current Cancer Therapy Reviews Effective Inhibition of Mitochondrial Metabolism by Cryptotanshinone in MDA-MB231 cells: A Proteomic Analysis
Current Proteomics Anti-cancer Scopes and Associated Mechanisms of Scutellaria Extract and Flavonoid Wogonin
Current Cancer Therapy Reviews Recent Patents on Devices and Technologies for Early Cancer Diagnostics
Recent Patents on Biomedical Engineering (Discontinued)